JØ
Therapeutic Areas
Bavarian Nordic Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JYNNEOS/IMVANEX/IMVAMUNE (MVA-BN) | Prevention of Smallpox and Mpox (Monkeypox) | Approved/Commercial |
| Rabipur/RabAvert | Prevention of Rabies | Approved/Commercial |
| Encepur | Prevention of Tick-Borne Encephalitis (TBE) | Approved/Commercial |
| VLA1553 | Prevention of Chikungunya Virus Infection | Phase 3 |
| MVA-BN RSV | Prevention of Respiratory Syncytial Virus (RSV) | Phase 3 |
| MVA-BN HIV | Prevention of HIV | Phase 2 |
| MVA-BN (Multi-Variant) | Prevention of COVID-19 | Phase 2 |
Leadership Team at Bavarian Nordic
PC
Paul Chaplin
President & Chief Executive Officer (CEO)
HJ
Henrik Juuel
Executive Vice President & Chief Financial Officer (CFO)
RS
Rolf Sass Sørensen
Executive Vice President, Chief Commercial Officer (CCO)
AS
Anders Søgaard Nielsen
Executive Vice President, Research & Development
BH
Bolette Højris
Senior Vice President, Quality & Regulatory Affairs